Table 1.
Baseline Characteristics | Placebo (n = 10) | Standard Deviation | Botulinum Toxin (n = 14) | Standard Deviation | p Value |
---|---|---|---|---|---|
Age, years (range) * | 60.5 (44–92) | 14.75 | 64 (37–78) | 13.49 | 0.94 |
Female (%) ** | 5 (62.5) | - | 6 (46.2) | - | 0.66 |
IRLS (range) * | 30.5 (25–38) | 4.66 | 27 (11–37) | 7.13 | 0.21 |
QOL (range) * | 34 (26–61) | 11.06 | 31 (18–44) | 7.93 | 0.24 |
MOS (range) * | 35.5 (27–43) | 4.99 | 38 (27–48) | 6.21 | 0.34 |
VAS (range) * | 5.5 (1–9) | 3.07 | 5 (0–10) | 3.07 | 0.27 |
ESS (range) * | 13.5 (3–23) | 7.18 | 10 (1–21) | 6.29 | 0.41 |
IRLS—International Restless Legs Syndrome (RLS) score, VAS—Visual Analog Scale, QOL—Johns Hopkins Quality of Life questionnaire, ESS—Epworth Sleepiness Scale, MOS—Sleep Scale from Medical Outcome Study. * Mann–Whitney U test; ** Fisher exact test.